NCT00240318CompletedPhase 3
A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 450
- Locations
- 61
- Primary Endpoint
- to evaluate whether 2 years of treatment with 40 mg rosuvastatin results in regression of coronary artery atheroma burden via the total atheroma volume in the most diseased segment or the percent atheroma volume, as measured by IVUS
Study Overview
Brief Summary
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical indication for coronary catheterization. Target Coronary Artery: The target vessel must have .50% reduction in lumen diameter by angiographic visual estimation throughout a segment of at least 40 mm in length (the target segment) and the vessel must be large enough to accommodate the IVUS catheter. A lesion of up to 60% is permitted distal to the target segment. Side branches of the target (imaged) vessel may be narrowed up to 70% by visual estimation, provided the target segment contains no lesion greater than 50%.
Exclusion Criteria
- •Use of lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis. Subjects receiving treatment with a lipid-lowering medication within the past 4 weeks require a 4-week wash-out period following which a baseline lipid profile will be taken at visit
- •Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study.
Outcomes
Primary Outcomes
to evaluate whether 2 years of treatment with 40 mg rosuvastatin results in regression of coronary artery atheroma burden via the total atheroma volume in the most diseased segment or the percent atheroma volume, as measured by IVUS
Secondary Outcomes
- to evaluate whether treatment with rosuvastatin results in:
- Regression of coronary artery atheroma burden, as assessed by TAV
- Regression of coronary artery disease as measured by quantitative coronary angiography (QCA).
- To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.
- To evaluate the safety of rosuvastatin
Investigators
Study Sites (61)
Loading locations...
Similar Trials
Unknown
Phase 4
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)AtherosclerosisHyperlipidemiaNCT00885872Chinese PLA General Hospital60
Completed
Phase 3
Rosuvastatin Impact on Ventricular Remodelling Lipids and CytokinesHeart Failure, CongestiveNCT00240292AstraZeneca160
Unknown
Phase 4
Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques VolumeCoronary Artery DiseaseHyperlipidemiaNCT01382277Peking University First Hospital600
Completed
Phase 4
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic SyndromeMetabolic SyndromeNCT00815659AstraZeneca97
Completed
Phase 3
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatinFamilial HypercholesterolemiaNCT00355615AstraZeneca173